Amarin Corporation plc (AMRN)
After hours:
| Previous Close | 1.2100 |
| Open | 1.2000 |
| Bid | 1.1400 x 28000 |
| Ask | 1.2000 x 27000 |
| Day's Range | 1.1350 - 1.2100 |
| 52 Week Range | 1.0400 - 5.2400 |
| Volume | |
| Avg. Volume | 3,325,015 |
| Market Cap | 479.815M |
| Beta (5Y Monthly) | 1.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0560 |
| Earnings Date | Aug 03, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.57 |
- GlobeNewswire
Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. H.C. Wainwright 24th Annual Global Investment Conference (September 12-14th, 2022; New York, New York) Date/Time: September 12, 2022, 9:00 a.m. ET/ 1:00 p.m. GMT+1 Webcast: https://journey.ct
- GlobeNewswire
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
-- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis -- -- Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular Pharmacotherapy -- DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 28, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new RED
- Motley Fool
Why Amarin Stock Was Plunging This Week
As of Friday before the market open, Amarin's stock was down by nearly 18% week to date, according to data provided by S&P Global Market Intelligence. Last Friday after market close, Amarin disclosed in a regulatory filing that it is ceasing operations in Germany, effective Sept. 1. The move comes after discussions with healthcare officials in that country failed to produce a reimbursement price Amarin considered "viable," in its words, for Vazkepa.
